The University of Oxford is part of a £15.9 million UK-wide programme to develop human tumour tissue models, improving cancer research, accelerating drug discovery and reducing reliance on animal testing.
In Bangladesh, children are fighting a difficult battle to survive antibiotic resistance - now, mid-pandemic, pneumonia is becoming untreatable via normal drugs.
The REACH study found that 97% of women and girls in Uganda, South Africa and Zimbabwe are happy to work with HIV prevention methods - globally, half of all people living with HIV are women.
Soraiya Verjee, Business Development Director of Sea Monster, discusses how the use of games and animation can combat COVID-19 and vaccine misinformation.
SAGE reveal that in the most pessimistic scenario, a further 115,800 COVID deaths would happen by June, 2022 - but in the most optimistic 'unlockdown' output, the figure is 9,400 deaths.
The FDA have labelled the Johnson & Johnson COVID vaccine as a possible cause of Guillain-Barré syndrome - an extremely rare side effect that can potentially cause nerve damage.
Davide Villa, business development director for EMEAI at Western Digital, discusses the data storage challenges in the healthcare industry and how they can be addressed.
An Australian team found that antibodies created by infection with the virus are not effective against COVID variants - suggesting that vaccination gives stronger protection.
The British Medical Association (BMA) today (7 July) responded to UK 'unlockdown' plans - labelling the suspension of all protective measures as "incoherent", with the NHS under "immense pressure".
With the current focus on public health worldwide, Arthur Goudena, Marketing Manager of PHC Europe, explains how one of Europe’s leading biobanks plays a growing role in supporting medical research.
SAGE say the UK Governments' plans to lift all social distancing measures on 19 July are too much - they believe a rise in infections will increase ethnic minority COVID deaths.
The team will have results to discuss in April, 2022 - they nurse the hope that this HIV vaccine could stop different geographical strains, after 40 years of no cure.
While mRNA is now well-connected to Pfizer or Moderna, saRNA is a more obscure, early-stage vaccine technology - now, scientists in the UK have data suggesting that saRNA COVID vaccines could work well for most people.
A study released yesterday (28 June) found that it would be safe to mix Pfizer and AstraZeneca doses, which could speed up UK vaccine roll-out if adopted.
Indiana University School of Medicine researchers are attempting to use magnetic nanoparticles to develop a cure for neurological disorders from epilepsy to Alzheimer's - without any invasive or genetic treatment.
The UK Government will begin rollout of a third COVID dose for over-50s and vulnerable individuals, with the NHS given the go-ahead to create their pre-winter vaccination plan.
